OptimizeRx Co. (NASDAQ:OPRX) CEO William J. Febbo Purchases 5,000 Shares

OptimizeRx Co. (NASDAQ:OPRX) CEO William J. Febbo bought 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The stock was bought at an average cost of $10.38 per share, for a total transaction of $51,900.00.

NASDAQ:OPRX opened at $10.13 on Friday. The stock has a market cap of $170.46 million, a PE ratio of 202.60, a P/E/G ratio of 1.50 and a beta of 0.42. OptimizeRx Co. has a 52 week low of $8.92 and a 52 week high of $17.24. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.01. The business’s 50-day simple moving average is $13.49 and its two-hundred day simple moving average is $14.42.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.11) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.04 by ($0.15). The company had revenue of $5.00 million during the quarter, compared to analysts’ expectations of $7.21 million. OptimizeRx had a negative return on equity of 4.19% and a negative net margin of 5.32%. Sell-side analysts anticipate that OptimizeRx Co. will post 0.2 earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the business. Strs Ohio purchased a new position in shares of OptimizeRx during the second quarter valued at approximately $51,000. Atlantic Trust LLC purchased a new position in shares of OptimizeRx during the second quarter valued at approximately $126,000. Wells Fargo & Company MN boosted its position in shares of OptimizeRx by 9.5% during the second quarter. Wells Fargo & Company MN now owns 13,562 shares of the company’s stock valued at $219,000 after buying an additional 1,180 shares during the period. Charles Schwab Investment Management Inc. purchased a new position in shares of OptimizeRx during the second quarter valued at approximately $454,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of OptimizeRx during the second quarter valued at approximately $488,000. Institutional investors and hedge funds own 57.32% of the company’s stock.

A number of equities analysts recently commented on the company. ValuEngine raised OptimizeRx from a “buy” rating to a “strong-buy” rating in a report on Wednesday. B. Riley decreased their target price on OptimizeRx from $26.00 to $21.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Zacks Investment Research cut OptimizeRx from a “hold” rating to a “sell” rating in a report on Tuesday, November 5th.

OptimizeRx Company Profile

OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.

Further Reading: Investing in Blue-Chip Stocks

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.